• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

能实现水溶性模型药物化合物近恒速释放的聚酸酐微球。

Polyanhydride microspheres that display near-constant release of water-soluble model drug compounds.

作者信息

Tabata Y, Langer R

机构信息

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge 02139.

出版信息

Pharm Res. 1993 Mar;10(3):391-9. doi: 10.1023/a:1018988222324.

DOI:10.1023/a:1018988222324
PMID:8464812
Abstract

A new method to prepare polyanhydride microspheres capable of near-constant sustained release of low molecular weight, water-soluble molecules is presented. The polyanhydrides used were poly(fatty acid dimer) (PFAD), poly(sebacic acid) (PSA), and their copolymers [P(FAD-SA)]. Acid orange 63 (AO), acid red 8 (AR), and p-nitroaniline, were used as model release molecules. P(FAD-SA) microspheres containing the molecules with or without gelatin were prepared by a modified solvent evaporation method using a double emulsion. The microspheres were spherical with diameters of 50-125 microns and encapsulated more than 85% of the molecule, irrespective of the compound used. Near-zero-order degradation kinetics were observed for 5 days as judged by sebacic acid (SA) release. Microsphere degradation was pH sensitive, being enhanced at high pH, and became more stable in acidic conditions, irrespective of the incorporation of gelatin in the matrix. For the gelatin-free microspheres, a close correlation of SA release and AO release was observed (2% loading), suggesting a release mechanism that was controlled dominantly by degradation. However, the incorporation of gelatin into the microsphere significantly extended the periods of molecule release from P(FAD-SA) microspheres, although the degradation profile of the microspheres themselves was quite similar to that of gelatin-free microspheres. It is possible that an interaction between FAD monomers and gelatin molecules causes continued release, even after the polymer matrix completely degrades (even after complete degradation, FAD monomers remain because of their poor water solubility). Thermal analysis of polyanhydride microspheres at different degradation stages demonstrated that a crystalline structure was formed between gelatin and the FAD monomers produced with microsphere degradation.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本文介绍了一种制备聚酸酐微球的新方法,该微球能够近乎恒定地持续释放低分子量水溶性分子。所用的聚酸酐为聚(脂肪酸二聚体)(PFAD)、聚(癸二酸)(PSA)及其共聚物[P(FAD-SA)]。酸性橙63(AO)、酸性红8(AR)和对硝基苯胺用作模型释放分子。通过改进的溶剂蒸发法使用双乳液制备了含有或不含有明胶的含分子的P(FAD-SA)微球。微球呈球形,直径为50-125微米,无论使用何种化合物,均能包封超过85%的分子。通过癸二酸(SA)释放判断,观察到5天内降解动力学接近零级。微球降解对pH敏感,在高pH下增强,在酸性条件下更稳定,与基质中是否加入明胶无关。对于无明胶微球,观察到SA释放与AO释放密切相关(负载量为2%),表明释放机制主要受降解控制。然而,将明胶掺入微球中显著延长了分子从P(FAD-SA)微球中释放的时间,尽管微球本身的降解曲线与无明胶微球非常相似。即使聚合物基质完全降解后(由于其水溶性差,即使完全降解后FAD单体仍保留),FAD单体与明胶分子之间的相互作用也可能导致持续释放。对不同降解阶段的聚酸酐微球进行热分析表明,明胶与微球降解产生的FAD单体之间形成了晶体结构。(摘要截断于250字)

相似文献

1
Polyanhydride microspheres that display near-constant release of water-soluble model drug compounds.能实现水溶性模型药物化合物近恒速释放的聚酸酐微球。
Pharm Res. 1993 Mar;10(3):391-9. doi: 10.1023/a:1018988222324.
2
Controlled delivery systems for proteins using polyanhydride microspheres.
Pharm Res. 1993 Apr;10(4):487-96. doi: 10.1023/a:1018929531410.
3
Synthesis and characterization of novel poly(sebacic anhydride-co-Pluronic F68/F127) biopolymeric microspheres for the controlled release of nifedipine.用于硝苯地平控释的新型聚(癸二酸酐 - 共聚普朗尼克F68/F127)生物聚合物微球的合成与表征
Int J Pharm. 2007 Dec 10;345(1-2):51-8. doi: 10.1016/j.ijpharm.2007.05.036. Epub 2007 May 23.
4
Degradation of porous poly(anhydride-co-imide) microspheres and implications for controlled macromolecule delivery.多孔聚(酸酐 - 共 - 酰亚胺)微球的降解及其对大分子可控递送的意义。
Biomaterials. 1998 Jan-Feb;19(1-3):163-72. doi: 10.1016/s0142-9612(97)00221-4.
5
Injectable polyanhydride granules provide controlled release of water-soluble drugs with a reduced initial burst.
J Pharm Sci. 1994 Jan;83(1):5-11. doi: 10.1002/jps.2600830104.
6
Poly(fumaric-co-sebacic anhydride). A degradation study as evaluated by FTIR, DSC, GPC and X-ray diffraction.聚(富马酸 - 共 - 癸二酸酐)。通过傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)、凝胶渗透色谱法(GPC)和X射线衍射进行评估的降解研究。
J Control Release. 1999 Jun 28;60(1):11-22. doi: 10.1016/s0168-3659(99)00016-4.
7
Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheres.聚合物化学和制备方法对聚酸酐微球中蛋白质释放和稳定性的影响。
J Biomed Mater Res B Appl Biomater. 2009 Nov;91(2):938-947. doi: 10.1002/jbm.b.31478.
8
In vitro release of model compounds with different hydrophilicity from poly(ester-anhydride) microspheres.不同亲水性模型化合物从聚(酯-酸酐)微球中的体外释放
Acta Pol Pharm. 2013 Nov-Dec;70(6):1051-63.
9
Evaluation of polyanhydride microspheres for basal insulin delivery: Effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo absorption and bioactivity in diabetic rats.聚酸酐微球用于基础胰岛素给药的评价:共聚物组成和锌盐对包封、体外释放、稳定性、糖尿病大鼠体内吸收和生物活性的影响。
J Pharm Sci. 2009 Nov;98(11):4237-50. doi: 10.1002/jps.21741.
10
Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres.微球大小、沉淀动力学和药物分布控制着可生物降解聚酸酐微球的药物释放。
J Control Release. 2004 Jan 8;94(1):129-41. doi: 10.1016/j.jconrel.2003.09.011.

引用本文的文献

1
Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression.基于聚集抑制 scFv 的治疗可保护小鼠免受 AAV1/2 诱导的 A53T-α-突触核蛋白过表达的影响。
Biomolecules. 2023 Jul 31;13(8):1203. doi: 10.3390/biom13081203.
2
Nanoparticle Strategies to Improve the Delivery of Anticancer Drugs across the Blood-Brain Barrier to Treat Brain Tumors.改善抗癌药物通过血脑屏障递送以治疗脑肿瘤的纳米颗粒策略。
Pharmaceutics. 2023 Jun 23;15(7):1804. doi: 10.3390/pharmaceutics15071804.
3
An Overview of Microparticulate Drug Delivery System and its Extensive Therapeutic Applications in Diabetes.

本文引用的文献

1
Present and future applications of biomaterials in controlled drug delivery systems.
Biomaterials. 1981 Oct;2(4):201-14. doi: 10.1016/0142-9612(81)90059-4.
2
Controlled release of biologically active compounds from bioerodible polymers.
Biomaterials. 1980 Jan;1(1):51-7. doi: 10.1016/0142-9612(80)90060-5.
3
Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics.可生物降解聚酸酐作为药物载体基质。I:表征、降解及释放特性。
J Biomed Mater Res. 1985 Oct;19(8):941-55. doi: 10.1002/jbm.820190806.
4
微颗粒药物递送系统概述及其在糖尿病中的广泛治疗应用
Adv Pharm Bull. 2022 Aug;12(4):730-746. doi: 10.34172/apb.2022.075. Epub 2021 Oct 4.
4
Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy.基于聚酸酐纳米颗粒的线粒体靶向抗氧化疗法对神经元氧化损伤的保护作用。
Nanomedicine. 2017 Apr;13(3):809-820. doi: 10.1016/j.nano.2016.10.004. Epub 2016 Oct 19.
5
Nano-enabled delivery of diverse payloads across complex biological barriers.纳米技术实现多种载荷跨越复杂生物屏障的递送。
J Control Release. 2015 Dec 10;219:548-559. doi: 10.1016/j.jconrel.2015.08.039. Epub 2015 Aug 24.
6
Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines.为纳米神经医学启用纳米材料、纳米制造和细胞技术。
Nanomedicine. 2015 Apr;11(3):715-29. doi: 10.1016/j.nano.2014.12.013. Epub 2015 Jan 31.
7
Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis.可生物降解微球表面性质的影响:对血浆蛋白吸附和吞噬作用的影响。
Pharm Res. 1998 Feb;15(2):312-7. doi: 10.1023/a:1011935222652.
8
Controlled delivery systems for proteins using polyanhydride microspheres.
Pharm Res. 1993 Apr;10(4):487-96. doi: 10.1023/a:1018929531410.
9
Development and characterization of microencapsulated microspheres.
Pharm Res. 1994 Nov;11(11):1568-74. doi: 10.1023/a:1018901619230.
Polyanhydride microsphere formulation by solvent extraction.
J Pharm Sci. 1988 Aug;77(8):696-8. doi: 10.1002/jps.2600770811.
5
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.采用药物聚合物植入物进行间质化疗治疗复发性胶质瘤。
J Neurosurg. 1991 Mar;74(3):441-6. doi: 10.3171/jns.1991.74.3.0441.